Astrazeneca Delisting

The regulator also said it came across certain reports that the offer for sale (OFS) of the shares of Astrazeneca Pharma India Ltd carried out by its promoter AstraZeneca Pharmaceuticals AB Sweden on May 26, 2013 was a deliberate attempt to subsequently get the shares of the Indian unit delisted at ease.

Suspecting violation of norms to check fraudulent and unfair trades, Sebi on Tuesday ordered close monitoring of a proposed delisting of Indian unit of global pharma giant AstraZeneca.

Essar Oil gained as much as 4.97 per cent to its daily limit after the company's board approved a proposal to delist the company from the exchanges.

AstraZeneca Pharma India's stock has risen nearly 50 percent from the year's low on January 30 to touch Rs 1,092.35 on Friday on delisting expectations, while the Mumbai market rose roughly 12 percent in that period.

Shares in AstraZeneca Pharma India surged as much as 7.6 per cent on Tuesday after the company says its board approved a proposal from promoter AstraZeneca Pharmaceuticals AB, Sweden to delist the company from India.

AstraZeneca Pharma India on Thursday said its board will meet later this week to consider delisting the company from various bourses including Bombay Stock Exchange (BSE) and National Stock Exchange (NSE).

Pending receipt of such additional information, consideration of the promoter's letter dated March 01, 2014 was deferred, said Astrazeneca Pharma in a communication to the BSE.

Astrazenaca Pharma India has surged 47 per cent in the past 4 trading sessions on expectation that the delisting price would be at a substantial premium to the existing market price of the company.

AstraZeneca Pharma India said in the filing before markets opened on Monday that its board received a request from its promoter, AstraZeneca Pharmaceuticals AB (AZP AB) Sweden, to initiate a voluntary delisting process.

Astrazeneca Pharma India lost 4.34% to Rs 1,302.05 on BSE on profit booking after the parent firm AstraZeneca Pharma AB pegged a tentative maximum price of Rs 1,152 per share to buyout the remaining 10% stake in the Indian unit. Meanwhile, the BSE Sensex was provisionally up 172.74 points, or 0.99%, to 17,643.77On BSE, 9,760 shares were traded in t...

Astrazeneca Pharma India fell 2.63% to Rs 1,300 at 9:38 IST after the company's Swedish founder set a floor price of Rs 576.10 a share to buyout the remaining 10% stake and delist the company.The announcement was made after market hours on Tuesday, 6 July 2010. The floor price is 55.68% discount to the ruling market price.Meanwhile, the BSE Sensex ...

AstraZeneca Pharma India hit upper circuit limit of 20% at Rs 1,207.05 on BSE after the company said its board will meet today, 29 June 2010, to consider delisting its shares from the stock exchanges.The announcement was made before trading hours today, 29 June 2010. Meanwhile, the BSE Sensex was down 64.39 points, or 0.37%, to 17,707.87. On BSE, 1...

AstraZeneca Pharma India soared 9.74% to Rs 1,324.60 at 12:57 IST after the company's board approved a proposal for delisting its shares from the stock exchanges.The announcement was made during trading hours on Tuesday, 29 June 2010, when the stock had jumped of 20% to Rs 1207.05. The stock has jumped 46.91% in five sessions from a recent low of R...

AstraZeneca Pharma India hit upper circuit limit of 20% at Rs 1,207.05 on BSE after the company said its board will meet today, 29 June 2010, to consider delisting its shares from the stock exchanges. The announcement was made before trading hours today, 29 June 2010. Meanwhile, the BSE Sensex was down 64.39 points, or 0.37%, to 17,707...

MUMBAI, SEPTEMBER 29: AstraZeneca Pharma India Ltd Tuesday said its shareholders have rejected the proposal for delisting of equity shares of the company. In a media release, the company said it had appealed for shareholder approval via a postal ballot on Aug 12. Tuesday, AstraZeneca Pharma share ended at Rs 1,087.50 on National Stock Exchange,...

The regulator also said it came across certain reports that the offer for sale (OFS) of the shares of Astrazeneca Pharma India Ltd carried out by its promoter AstraZeneca Pharmaceuticals AB Sweden on May 26, 2013 was a deliberate attempt to subsequently get the shares of the Indian unit delisted at ease.

Suspecting violation of norms to check fraudulent and unfair trades, Sebi on Tuesday ordered close monitoring of a proposed delisting of Indian unit of global pharma giant AstraZeneca.

Essar Oil gained as much as 4.97 per cent to its daily limit after the company's board approved a proposal to delist the company from the exchanges.

AstraZeneca Pharma India's stock has risen nearly 50 percent from the year's low on January 30 to touch Rs 1,092.35 on Friday on delisting expectations, while the Mumbai market rose roughly 12 percent in that period.

Shares in AstraZeneca Pharma India surged as much as 7.6 per cent on Tuesday after the company says its board approved a proposal from promoter AstraZeneca Pharmaceuticals AB, Sweden to delist the company from India.

AstraZeneca Pharma India on Thursday said its board will meet later this week to consider delisting the company from various bourses including Bombay Stock Exchange (BSE) and National Stock Exchange (NSE).

Pending receipt of such additional information, consideration of the promoter's letter dated March 01, 2014 was deferred, said Astrazeneca Pharma in a communication to the BSE.

Astrazenaca Pharma India has surged 47 per cent in the past 4 trading sessions on expectation that the delisting price would be at a substantial premium to the existing market price of the company.

AstraZeneca Pharma India said in the filing before markets opened on Monday that its board received a request from its promoter, AstraZeneca Pharmaceuticals AB (AZP AB) Sweden, to initiate a voluntary delisting process.

Astrazeneca Pharma India lost 4.34% to Rs 1,302.05 on BSE on profit booking after the parent firm AstraZeneca Pharma AB pegged a tentative maximum price of Rs 1,152 per share to buyout the remaining 10% stake in the Indian unit. Meanwhile, the BSE Sensex was provisionally up 172.74 points, or 0.99%, to 17,643.77On BSE, 9,760 shares were traded in t...

Astrazeneca Pharma India fell 2.63% to Rs 1,300 at 9:38 IST after the company's Swedish founder set a floor price of Rs 576.10 a share to buyout the remaining 10% stake and delist the company.The announcement was made after market hours on Tuesday, 6 July 2010. The floor price is 55.68% discount to the ruling market price.Meanwhile, the BSE Sensex ...

AstraZeneca Pharma India hit upper circuit limit of 20% at Rs 1,207.05 on BSE after the company said its board will meet today, 29 June 2010, to consider delisting its shares from the stock exchanges.The announcement was made before trading hours today, 29 June 2010. Meanwhile, the BSE Sensex was down 64.39 points, or 0.37%, to 17,707.87. On BSE, 1...

AstraZeneca Pharma India soared 9.74% to Rs 1,324.60 at 12:57 IST after the company's board approved a proposal for delisting its shares from the stock exchanges.The announcement was made during trading hours on Tuesday, 29 June 2010, when the stock had jumped of 20% to Rs 1207.05. The stock has jumped 46.91% in five sessions from a recent low of R...

AstraZeneca Pharma India hit upper circuit limit of 20% at Rs 1,207.05 on BSE after the company said its board will meet today, 29 June 2010, to consider delisting its shares from the stock exchanges. The announcement was made before trading hours today, 29 June 2010. Meanwhile, the BSE Sensex was down 64.39 points, or 0.37%, to 17,707...

MUMBAI, SEPTEMBER 29: AstraZeneca Pharma India Ltd Tuesday said its shareholders have rejected the proposal for delisting of equity shares of the company. In a media release, the company said it had appealed for shareholder approval via a postal ballot on Aug 12. Tuesday, AstraZeneca Pharma share ended at Rs 1,087.50 on National Stock Exchange,...